Ocugen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Dry Eye Disease Study With Brimonidine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 84
- Registration Number
- NCT03418727
- Locations
- 🇺🇸
Brenart Eye Clinic, Yorkville, Illinois, United States
🇺🇸Chicago Cornea Consultants, Hoffman Estates, Illinois, United States
🇺🇸The Eye Institute of Utah, Salt Lake City, Utah, United States
© Copyright 2024. All Rights Reserved by MedPath